Shots:
Pierre Fabre has partnered with RedRidge for BPA drugs against various targets in oncology, dermatology & rare diseases, where the latter will engineer, screen, & characterize BPAs for jointly selected targets, while Pierre will advance 2 co-development programs
As per the deal, RedRidge will hold marketing rights in the US, Canada, & Japan…
